Children's cancer group recommends global evaluation system for neuroblastoma to improve treatment

December 08, 2008

An international coalition of pediatric cancer physicians and researchers has developed new systems to standardize studies of neuroblastomas across the world. In the December issue of the Journal of Clinical Oncology, the International Neuroblastoma Risk Group (INRG) presents three sets of papers outlining a: standard classification system; pre-treatment staging system; and an analysis of a rare group of patients.

The INRG studies provide for a unified system of clinical trials that will enable quicker identification of optimal treatments for neuroblastoma.

Neuroblastoma is the most common solid cancer that occurs outside the cranium during childhood. For some young children, it disappears with minimal treatment. In other children, it can be relentlessly aggressive, with a high likelihood of death. Predicting the behavior of this tumor is crucial in planning appropriate treatment.

The INRG task force is co-chaired by Susan Cohn, professor and director of clinical sciences at the University of Chicago Comer Children's Hospital, and Andrew Pearson, chairman of paediatric oncology at the Institute of Cancer Research at Royal Marsden Hospital in the UK.

Cohn says that in the past, criteria used to predict tumor behavior and stratify treatment have not been uniform throughout the world, which makes it impossible to directly compare clinical trial results. The INRG classification system is designed to create consistency of risk group assignment around the globe, and will facilitate clinical research.

"We strongly recommend that cooperative groups begin using this classification system now," Cohn says.

"The system will allow the direct comparison of results from clinical trials conducted in different regions of the world and will help us determine the best treatment strategies for patients with neuroblastoma," she adds. "By working together, physicians will be able to ask questions about treatment approaches that would otherwise not be possible to ask in a single cooperative group or country because of the small numbers of patients. We plan to continue to expand this database, and as new molecular tools are developed to test cancer genetics, the INRG Classification System will be refined."
-end-
Formed in 2004, the INRG task force has 52 members working to develop a standard worldwide approach to classify neuroblastomas before treatment. The criteria included in the INRG classification system were based on an analysis of 8,800 children under age 21 who were diagnosed with neuroblastoma between 1990-2002. They were primarily from North America, Australia, Europe, and Japan. Among the seven predictors of how the neuroblastoma will progress are stage of the cancer as defined by INRG standards, histology, patient's age, and genetic factors.

The INRG database has also proven to be an invaluable resource for additional research. The third paper in the issue of the Journal of Clinical Oncology describes an analysis of a very rare subset of patients with low-stage disease and amplification of the MYCN oncogene.

The study was funded, in part, by the William Guy Forbeck Research Foundation and the Little Heroes Pediatric Cancer Research Foundation.

Additional study authors for the three studies include Wendy London, Tom Monclair, Peter Ambros, Garrett Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Veronique Mosseri, Thorsten Simon, Victoria Castel, Katherine Matthay, Keith Holmes, Alberto Garaventa, Giovanni Cecchetto, Herve Brisse, Michio Kaneko, Jed Nuchtern, Dietrich von Schweinitz, Rochelle Bagatell, Maja Beck-Popovic, and Yang Zhang.

University of Chicago Medical Center

Related Neuroblastoma Articles from Brightsurf:

Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.

Researchers mine data and connect the dots about processes driving neuroblastoma
St. Jude Children's Research Hospital scientists lead genome analysis to better understand one of the most common childhood solid tumors.

Promising treatment for aggressive childhood cancer
A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer.

MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma
The researchers adopted the functional polymorphism research strategy to screen out the functional polymorphisms associated with neuroblastoma in Chinese population and elucidate its mechanism, providing data on children susceptible to neuroblastoma in China.

A novel radioisotope therapy for children with neuroblastoma
Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital.

New method for monitoring residual disease after treatment in children with neuroblastoma
Neuroblastoma is a cancer that affects children, characterized by solid tumors that develop from immature nerve cells.

Research sheds important light on the metastasis of neuroblastoma
Research sheds important light on the metastasis of neuroblastoma.

A step forward in the struggle against neuroblastoma, a type of childhood cancer
A protein called CD44 makes it possible to identify the population of mother cells that are responsible for the aggressive nature and low survival rate of neuroblastoma, a type of childhood cancer that mainly affects children of two and three years old.

More children survive neuroblastoma
Both the survival rate and the incidence of neuroblastoma have increased in the last decennia in the Netherlands, as was shown by a study from the Princess Máxima Center.

TTUHSC researchers publish preclinical data on new drug combination to treat neuroblastoma
Neuroblastoma, the most common cancer outside of the brain in infants and young children, often fails to respond to therapy.

Read More: Neuroblastoma News and Neuroblastoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.